Description

The CDx/Biomarkers & Biobanking event will bring together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, Biobanking and leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers—making the conference a perfect meeting-place to share experience, foster collaborations across industry and academia, evaluate emerging technologies and all aspects of the biomarker and diagnostic development process from discovery to translation to commercialization.

CDx market is growing due to continuous advancement in medical technology both for the diagnosis and the treatment of patients. Rise in the prevalence of diseases like cancer & HIV is fueling to the growth of companion diagnostics as it assist in determining the patient specific dose and drugs. The Biomarkers Market is expected to register a CAGR of 10.28% during the assessment period of 2020 to 2027, to reach USD 4,5B by 2027. With an increasing incidence rate of chronic and life-threatening diseases, the demand for precise diagnostic procedures is increasing. In addition to that, there is an increase in the number of manufacturers, distributors, and service providers of biomarkers across the globe, creating enormous growth opportunities in the market.

Beyond the CDx & Biomarkers, this conference will also gather biobanking leaders from the north Europe, as well as from across the Atlantic, in order to zoom in the market prospects and understand the dynamics of this fast-paced growing industry. Geographically, the EMEA region is estimated to account for a market share of approximately 44% during the predicted period. The presence of a well-established biobanking system in the Nordic countries, such as Sweden, Norway, Denmark, Finland, and Iceland, is a significant factor that bolsters market growth in this region.

The CDx, Biomarkers & Biobanking event will insight into how the biobanking industry at the forefront at driving precision medicine and the opportunities and challenges of biomarker research discovery and development in a variety of therapeutic areas such as immune-oncology, neuroscience and cardio vascular disease areas, precision medicine, companion diagnostics, data integration methods, and utilising biomarkers in clinical trials. We will also cover the most relevant hot topics including: biospecimen science, management, and applications, bringing together biomedical and biopharmaceutical researchers, regulators, biorepository managers and practitioners to investigate the best strategies for effective use of biospecimens within today’s cutting-edge biomedical research, leading to the goal of personalized medicine.

Key Practical Points

CDx & Biomarkers

  • Learn the recent advances and future perspectives in CDx & Biomarkers
  • Understand the key aspects & challenges of Clinical Biomarker development & qualification Solutions for clinical development of precision therapies
  • Predictive Biomarkers and Companion Diagnostics for Immuno-Oncology
  • Proteomics and Genomics based Biomarkers
  • Epigenetic biomarkers in saliva
  • Regulatory landscapes for biomarkers and diagnostic tests
  • Digital Biomarkers, Predictive Biomarkers, Precision Medicine and Big Data
  • Main barriers to progression of precision medicine in drug development
  • The Role of In Vitro Diagnostics in Successful Precision Medicine Market Access
  • Options for biomarker based patient stratification in NON-ONCOLOGY clinical development
  • Clinical Applications of Biomarkers in Immuno-Oncology, Neurology and Inflammatory Diseases
  • Key trends in targeted and immuno-oncology companion diagnostics
  • Clinical applications of liquid biopsies
  • Genomics challenges from a single sample to large clinical studies
  • Tissue Microarray Technology for Biomarker Validation and Discover
  • Design of clinical trials in CDx

Biobanking

  • How AI and biobanks address global challenges
  • Understand the opportunities and challenges of biosampling
  • Biobanking and personalized medicine in oncology
  • Learn the latest technological methods and procedures for biopreservation, storage stability and validation, while naming evidence-based best practices
  • Explore new sample quality management systems, quality standards and accreditation
  • Novel IT solutions, effective data storage, processing and analysis
  • Learn how to maintain a sustainable infrastructure in biobanking
  • Debate the social and ethical challenges of biobanking for human research
  • Predict the market impact of biobanking in the next decade
  • Current market trends and future challenges for biobanking success
  • Biobanking development in emerging markets
  • Prognosis for the Global Biobanking market in an era of transformative new technologies
  • Returning Genetic Results in a Population Cohort
  • Redesigning the biobanking business model
  • Clinical Trial Strategies in Biobanking and Drug Development
  • Starting Materials and Standards for Stem Cell-based Therapies

Who should attend?

Members of board, C-level, Senior Vice Presidents, Vice Presidents, Directors and Heads of departments from pharmaceutical/biotechnology industry / industries involved in:

  • Companion Diagnostics
  • Molecular Diagnostics
  • Personalized Healthcare
  • Clinical Development
  • Regulatory Affairs
  • Molecular Diagnostics
  • Biomarkers
  • Medical Sciences
  • Experimental Medicine
  • Translational Medicine
  • Immunology
  • Genomics
  • Insurers
  • Patient Advocates
  • Payers
  • Market Access
  • Commercialization
  • Oncology
  • Non-oncology
  • Rare Diseases
  • Drug Development
  • Research
  • Biopharmaceuticals and Biologics
  • Researchers
  • Molecular Technologies
  • Intellectual property
  • Legislation and Policy Advice
  • Biobanking Researchers
  • Biobanking Faculty Members
  • Biobanking Associations and Societies
  • Training Institutes
  • Cryo storage Companies
  • Data Provacy and Management Companies
  • Security Officers
  • Global Biobanking Companies
  • Business Developers
  • Biobanking investors
  • Lab Managers
  • Drug and Safety Assessment
  • Market Strategy
  • Biopharmaceuticals
  • Clinical Immunology
  • Drug Safety Assessment & Risk Management
  • Population and Disease Based biobanks
  • Bioinnovation
  • Intellectual property
  • Regulatory Affairs
  • Health Economics Principal Scientists
  • Process Control and Analytical Technologies
  • Quality Affairs/ Quality Control
  • Regulatory Affairs
  • Regulatory Compliance
  • Legal Affairs
  • R&D
  • New Product Development
  • Health Economics
  • Process Control and Analytical Technologies

Keynote Speakers

Jane Wilkinson

Senior Director, Broad Genomics Alliance MNGT. at Broad Institute

Brent Schacter

Professor Emeritus at Rady College of Medicine, University of Manitoba

Catherine Alix-Panabières

Director of the Laboratory of Rare Human Circulating Cells (LCCRH)

Andres Metspalu

Head of the Estonian Biobank, Institute of Genomics, Univ. of Tartu

Video from Previous Edition